Lenz Therapeutics Stock Debt To Equity
| LENZ Stock | 37.30 1.05 2.90% |
LENZ Therapeutics fundamentals help investors to digest information that contributes to LENZ Therapeutics' financial success or failures. It also enables traders to predict the movement of LENZ Stock. The fundamental analysis module provides a way to measure LENZ Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to LENZ Therapeutics stock.
| Last Reported | Projected for Next Year |
LENZ | Debt To Equity |
LENZ Therapeutics Company Debt To Equity Analysis
LENZ Therapeutics' Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Current LENZ Therapeutics Debt To Equity | 0.001467 |
Most of LENZ Therapeutics' fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, LENZ Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
LENZ Debt To Equity Driver Correlations
Understanding the fundamental principles of building solid financial models for LENZ Therapeutics is extremely important. It helps to project a fair market value of LENZ Stock properly, considering its historical fundamentals such as Debt To Equity. Since LENZ Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of LENZ Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of LENZ Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
| Competition |
LENZ Total Stockholder Equity
Total Stockholder Equity |
|
LENZ Debt To Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses LENZ Therapeutics' direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of LENZ Therapeutics could also be used in its relative valuation, which is a method of valuing LENZ Therapeutics by comparing valuation metrics of similar companies.LENZ Therapeutics is currently under evaluation in debt to equity category among its peers.
LENZ Fundamentals
| Return On Equity | -1.58 | ||||
| Return On Asset | -0.77 | ||||
| Current Valuation | 406.07 M | ||||
| Shares Outstanding | 27.47 M | ||||
| Shares Owned By Insiders | 5.40 % | ||||
| Shares Owned By Institutions | 86.06 % | ||||
| Number Of Shares Shorted | 2.18 M | ||||
| Price To Book | 3.11 X | ||||
| EBITDA | (122.24 M) | ||||
| Net Income | (124.65 M) | ||||
| Total Debt | 362 K | ||||
| Book Value Per Share | 7.46 X | ||||
| Cash Flow From Operations | (90.01 M) | ||||
| Short Ratio | 17.72 X | ||||
| Earnings Per Share | (2.74) X | ||||
| Target Price | 33.8 | ||||
| Market Capitalization | 600.49 M | ||||
| Total Asset | 188.46 M | ||||
| Retained Earnings | (367.05 M) | ||||
| Annual Yield | 0.89 % | ||||
| Net Asset | 188.46 M |
About LENZ Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze LENZ Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of LENZ Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of LENZ Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for LENZ Stock Analysis
When running LENZ Therapeutics' price analysis, check to measure LENZ Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy LENZ Therapeutics is operating at the current time. Most of LENZ Therapeutics' value examination focuses on studying past and present price action to predict the probability of LENZ Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move LENZ Therapeutics' price. Additionally, you may evaluate how the addition of LENZ Therapeutics to your portfolios can decrease your overall portfolio volatility.